abnorm
proteinas
k
pk
resist
prion
protein
prpsc
known
compon
infecti
prion
associ
group
fatal
neurodegen
disord
call
prion
diseas
transmiss
spongiform
encephalopathi
well
document
prpsc
deriv
pksensit
cellular
prpc
central
nervou
system
alphahelix
betasheet
structur
transit
specif
molecular
mechan
behind
prp
convers
remain
poorli
understood
sever
plausibl
theori
emerg
includ
prevail
seed
model
explain
convers
use
prpsc
seed
introduc
either
exogen
infect
diseas
kuru
iatrogen
creutzfeldtjakob
diseas
cjd
variant
cjd
form
endogen
prpsc
molecul
includ
sporad
cjd
variou
famili
prion
diseas
howev
exact
molecular
natur
endogen
prpsc
elucid
first
identifi
small
amount
pkresist
prp
aggreg
uninfect
brain
human
cattl
hamster
sinc
subsequ
studi
reveal
similar
insolubl
structur
wide
rang
organ
cattl
sheep
human
cultur
neuroblastoma
cell
express
wildtyp
mutant
human
prp
studi
provid
experiment
evid
prionlik
form
present
low
level
normal
brain
isoform
could
either
silent
prion
prion
precursor
propos
previous
recogn
prp
speci
implic
longterm
memori
healthi
human
neuroblastoma
cell
express
variou
human
prp
mutant
essenti
tool
studi
mutant
prion
link
natur
occur
famili
prion
diseas
previous
use
two
model
express
either
mutat
residu
thr
ala
residu
phe
ser
discov
pkresist
prp
prpre
speci
exhibit
higher
affin
antiprp
monoclon
antibodi
epitop
residu
compar
antiprp
antibodi
antibodi
widelyus
detect
human
prion
epitop
residu
furthermor
demonstr
immunoreact
behavior
gel
mobil
prpre
virtual
ident
prp
observ
previous
uninfect
brain
valid
cell
model
investig
spontan
form
iprpc
studi
use
cell
express
prpwt
made
follow
observ
first
prp
mutat
increas
aggreg
protein
report
accumul
intracellularli
exhibit
highest
amount
iprp
second
immunofluoresc
microscopi
demonstr
lower
affin
prp
cultur
cell
immunoblot
third
glycan
second
site
basic
wherea
glycan
first
site
acid
fourth
mutat
abolish
glycosyl
also
alter
glycosyl
addit
immatur
glycan
report
previous
composit
may
also
chang
evidenc
faster
migrat
pkresist
compar
pkresist
prpsc
scjd
fifth
mutat
also
alter
glycosyl
first
second
site
glycosyl
diglycosyl
seem
matur
monoglycosyl
protein
use
monoclon
antibodi
differenti
two
monoglycosyl
prp
moudjou
et
al
observ
mutat
block
epitop
mimick
reduct
alkyl
reaction
often
break
disulfid
bond
prevent
reoxid
thiol
group
although
detect
unglycosyl
prp
prp
monoglycosyl
brain
prp
fail
detect
glycosyl
de
unglycosyl
prp
cultur
neuron
cell
final
electron
microscopi
reveal
cell
express
enhanc
autophagi
seem
complet
inhibit
autophagi
compar
wildtyp
cell
find
provid
new
insight
molecular
mechan
underli
format
iprpc
abnorm
fold
mutant
protein
first
predic
effect
molecular
weight
charg
protein
use
protparam
tool
websit
http
webexpasyorgprotparam
expasi
molecular
weight
wild
type
prion
protein
prpwt
backbon
residu
dalton
da
compar
prpwt
molecular
weight
decreas
da
vs
da
da
vs
da
although
molecular
weight
decreas
compar
wild
type
control
small
degre
chang
molecular
weight
might
detect
western
blot
addit
three
prp
molecul
exhibit
molecular
charg
theoret
isoelectr
point
pi
nlink
glycosyl
predict
algorithm
netnglyc
use
http
wwwcbsdtudkservicesnetnglyc
predict
likelihood
glycosyl
two
consensu
site
netnglyc
server
provid
glycosyl
potenti
valu
nlink
glycosyl
site
potenti
valu
greater
indic
glycosyl
probabl
site
use
algorithm
glycosyl
potenti
valu
prpwt
determin
respect
notabl
potenti
valu
greater
second
site
first
site
three
speci
test
prpwt
glycosyl
predict
mutat
almost
ident
prpwt
first
second
glycosyl
site
predict
respect
interestingli
though
potenti
valu
second
site
decreas
compar
prpwt
vs
suggest
mutat
mainli
affect
glycosyl
expect
would
mutat
phe
ser
would
increas
glycosyl
report
previous
alter
gel
profil
larg
effect
mutat
glycosyl
probe
antibodi
direct
prpwt
migrat
three
major
band
one
diglycosyl
kda
two
monoglycosyl
kda
kda
respect
one
unglycosyl
kda
form
fig
upper
panel
contrast
singl
band
migrat
kda
correspond
monoglycosyl
prp
detect
cell
lysat
express
cell
fig
upper
panel
band
migrat
kda
kda
correspond
di
monoglycosyl
form
respect
detect
cell
lysat
express
cell
unglycosyl
form
undetect
data
conclud
mainli
contain
monoglycosyl
prp
second
site
wherea
contain
one
di
two
separ
monoglycosyl
prp
occupi
first
treatment
pk
prp
detect
except
express
cell
weak
band
chang
migrat
remain
probe
band
undigest
contrast
use
antiprp
monoclon
antibodi
direct
untreat
prp
virtual
undetect
three
cell
lysat
pk
treatment
detect
mutant
wild
type
pkresist
form
fig
one
theori
uniqu
behavior
antibodi
epitop
block
fulllength
prp
even
subject
denatur
condit
prior
western
blot
becom
expos
truncat
pk
remov
approxim
amino
acid
nterminu
cell
lysat
probe
profil
pkresist
differ
sampl
reveal
intens
band
migrat
kda
correspond
pkresist
monoglycosyl
speci
fig
lower
panel
two
pkresist
band
kda
band
correspond
diglycosyl
prp
kda
band
correspond
monoglycosyl
prp
fig
lower
panel
interestingli
mobil
di
monoglycosyl
slightli
slower
pkresist
prpsc
scjd
fig
lower
panel
mobil
monoglycosyl
second
site
faster
monoglycosyl
form
cell
lysat
also
prpre
cjd
brain
control
monoglycosyl
carri
glycan
second
glycosyl
site
residu
monoglycosyl
form
prpre
cjd
brain
cultur
cell
slower
migrat
may
repres
glycan
first
glycosyl
site
residu
anoth
possibl
glycan
site
modifi
differ
consequ
migrat
slower
glycan
util
immunofluoresc
tag
microscopi
next
compar
cell
express
prpwt
immunostain
consist
western
blot
three
cell
type
exhibit
greater
immunostain
fig
notabl
although
weak
prpwt
two
prp
mutant
becam
detect
immunofluoresc
contrast
result
western
blot
shown
fig
addit
demonstr
previous
like
locat
intracellularli
wild
type
present
cell
surfac
immunostain
reduc
almost
insignific
level
wild
type
cell
treat
pk
fig
consist
western
blot
result
contrast
immunostain
decreas
pktreatment
opposit
observ
western
blot
sucros
step
gradient
sediment
techniqu
use
separ
prion
protein
speci
base
densiti
size
conform
gener
monom
small
oligom
often
recov
top
fraction
wherea
larg
aggreg
recov
bottom
fraction
ultracentrifug
sucros
step
gradient
increas
format
pkresist
prp
speci
cell
express
mutant
prp
might
associ
increas
aggreg
protein
distribut
prp
sucros
step
gradient
fraction
collect
ultracentrifug
determin
western
blot
probe
antibodi
expect
prpwt
recov
top
fraction
ie
fraction
wherea
small
amount
prp
observ
fraction
contrast
signific
amount
recov
bottom
fraction
wherea
detect
fraction
small
amount
prp
observ
fraction
fig
middl
panel
compar
prpwt
although
distribut
top
fraction
increas
amount
also
recov
bottom
fraction
especi
fraction
fig
lower
panel
determin
fraction
contain
pkresist
wildtyp
mutant
prp
treat
prp
fraction
pk
pngase
f
fig
pkresist
detect
fraction
probe
fraction
show
pkresist
addit
detect
pk
resist
wild
type
mutant
prp
sucros
gradient
fraction
detect
pkresist
iprp
three
prp
speci
highest
intens
mutant
prp
fig
howev
small
amount
pkresist
prp
observ
fraction
prpwt
wherea
larger
amount
pkresist
prp
detect
fraction
onedimension
electrophoresi
immunoblot
clearli
indic
glycan
two
nlink
glycosyl
site
pkresist
iprpc
differ
molecular
weight
monoglycosyl
prp
speci
second
site
residu
migrat
faster
monoglycosyl
first
site
residu
take
advantag
uniqu
mutat
elimin
first
retain
second
glycosyl
site
next
ask
whether
distinct
molecular
charg
twodimension
gel
electrophoresi
techniqu
separ
protein
base
molecular
weight
molecular
charg
gene
protein
first
use
isol
iprpc
three
type
cell
lysat
follow
previous
describ
protocol
similar
immunoblot
convinc
pkresist
prpwt
spot
detect
blot
data
shown
howev
two
pkresist
mutant
detect
although
prp
intens
former
fold
greater
use
compar
mutant
blot
probe
show
pkresist
prion
protein
migrat
kda
isoelectr
point
pi
ph
intens
spot
ph
also
detect
fig
arrow
spot
believ
correspond
sinc
first
glycosyl
site
elimin
mutat
mutant
protein
migrat
kda
pi
ph
base
molecular
weight
spot
repres
diglycosyl
prp
speci
fig
howev
spot
detect
use
antibodi
intens
notic
differ
blot
spot
detect
migrat
kda
correspond
mainli
detect
rang
ph
faint
spot
also
detect
ph
fig
spot
mainli
detect
ph
migrat
kda
correspond
diglycosyl
form
fig
two
popul
faint
prp
spot
migrat
kda
also
detect
ph
well
ph
correspond
spot
migrat
could
prp
speci
monoglycosyl
first
site
sinc
share
similar
molecular
weight
identifi
blot
fig
wherea
spot
ph
migrat
kda
could
monoglycosyl
second
site
fig
treatment
pk
pngase
f
two
mutant
exhibit
pkresist
form
wild
type
pkresist
form
detect
exhibit
similar
gel
mobil
kda
ph
blot
although
slight
differ
ph
intens
spot
fig
howev
sampl
probe
antibodi
pkresist
iprpc
becam
detect
even
prpwt
faint
wild
type
spot
migrat
kda
ph
fig
intens
pkresist
spot
detect
similar
gel
mobil
migrat
kda
ph
fig
furthermor
analys
glycosyl
deglycosyl
pkresist
mutant
iprp
indic
glycan
second
site
basic
wherea
glycan
first
site
acid
blot
similar
immunoblot
also
demonstr
higher
affin
pkresist
iprp
compar
indic
effect
two
mutat
charg
protein
predict
two
possibl
may
explain
slight
differ
ph
intens
spot
deglycosyl
three
type
protein
either
distinct
ntermin
proteas
cleavag
site
distinct
gpi
anchor
previou
studi
indic
pkresist
monoglycosyl
molecular
weight
lower
pkresist
monoglycosyl
prpsc
observ
may
due
two
possibl
first
may
abnorm
glycosyl
even
though
mutat
directli
elimin
second
molecular
weight
glycan
greater
howev
hypothesi
inconsist
previou
report
previou
studi
two
monoclon
antibodi
term
gener
use
recombin
sheep
prp
immunogen
produc
glycancontrol
epitop
prp
molecul
discrimin
two
monoglycosyl
speci
notabl
epitop
recogn
two
antibodi
identifi
crystal
structur
prpantibodi
complex
epitop
could
map
use
convent
peptid
scan
observ
epitop
local
sheep
correspond
human
wherea
epitop
determin
precis
yet
epitop
deduc
locat
region
amino
acid
first
glycosyl
site
interestingli
although
antibodi
recogn
unglycosyl
prp
bind
prp
first
asn
glycosyl
site
occupi
correspond
human
bind
prp
carri
second
glycosyl
site
correspond
human
sheep
human
hamster
mice
also
report
glycan
chain
smaller
first
glycosyl
site
second
site
first
examin
prpsc
untreat
treat
pk
alon
treat
pk
plu
pngase
f
scjd
brain
two
antibodi
without
pk
pngase
f
treatment
five
major
prp
band
detect
fig
base
molecular
weight
top
band
migrat
kda
repres
monoglycosyl
prp
speci
sinc
detect
prp
speci
monoglycosyl
band
second
band
migrat
kda
correspond
unglycosyl
fulllength
prp
third
band
migrat
monoglycosyl
fragment
first
site
occupi
fourth
band
migrat
kda
unglycosyl
fragment
endogen
ntermin
truncat
prp
fragment
detect
cjd
brain
final
fifth
band
migrat
kda
unglycosyl
ntermin
truncat
normal
brain
pktreatment
three
major
band
detect
top
band
migrat
pkresist
prp
monoglycosyl
first
site
pk
second
band
migrat
kda
pkresist
unglycosyl
prp
un
pk
third
faint
band
detect
kda
sampl
treat
pk
pngase
f
two
band
detect
domin
band
migrat
kda
migrat
kda
compar
sampl
treat
pk
without
pngase
f
band
migrat
kda
significantli
increas
suggest
new
fragment
contain
glycosyl
unglycosyl
form
moreov
sinc
detect
untreat
sampl
new
fragment
could
gener
pk
digest
vitro
fig
left
panel
although
equal
amount
sampl
use
gener
prp
intens
much
lower
sampl
probe
sampl
probe
fig
right
panel
intens
prp
band
untreat
prp
detect
weak
four
band
could
identifi
top
doubl
band
migrat
kda
correspond
prp
speci
monoglycosyl
second
glycosyl
site
pk
band
migrat
kda
correspond
unglycosyl
fulllength
prp
band
migrat
kda
repres
monoglycosyl
second
site
treatment
pk
two
band
becam
detect
migrat
kda
kda
respect
sinc
detect
monoglycosyl
speci
occupi
residu
repres
pkresist
prp
speci
monoglycosyl
second
site
pk
pkresist
deglycosyl
unglycosyl
form
un
pk
consist
observ
moudjou
et
al
migrat
prp
detect
slower
prp
detect
fig
therefor
use
two
antibodi
observ
human
pkresist
prp
speci
monoglycosyl
second
site
higher
molecular
weight
monoglycosyl
first
site
addit
antibodi
unabl
detect
diglycosyl
human
prp
consist
previou
observ
moudjou
et
al
cultur
neuron
cell
lysat
contain
prpwt
four
major
band
detect
migrat
kda
kda
kda
kda
fig
left
panel
correspond
unglycosyl
prp
unglycosyl
compar
prpsc
scjd
fig
dramat
decreas
uninfect
cell
lysat
treatment
pngase
f
two
band
detect
correspond
deglycosyl
fulllength
kda
ntermin
truncat
kda
mainli
detect
unglycosyl
migrat
kda
faint
band
also
detect
migrat
kda
kda
correspond
respect
fig
left
panel
deglycosyl
pngase
f
two
band
correspond
deglycosyl
unglycosyl
fulllength
ntermin
truncat
prp
molecul
detect
contrast
band
detect
treat
untreat
cell
lysat
contain
surprisingli
prp
band
detect
three
cell
lysat
untreat
treat
pngase
f
fig
right
panel
use
two
antibodi
unabl
address
issu
migrat
faster
inabl
detect
inabl
detect
wildtyp
mutant
prp
cultur
cell
lysat
nevertheless
current
studi
reveal
identifi
monoglycosyl
second
glycosyl
site
moreov
new
result
first
time
indic
mutat
block
bind
prp
epitop
complet
block
wildtyp
mutant
prp
cultur
cell
inabl
detect
rais
two
possibl
first
residu
phe
key
element
epitop
mutat
complet
block
bind
howev
residu
phe
epitop
demonstr
xray
crystallographi
studi
support
possibl
second
although
residu
phe
part
epitop
mutat
may
affect
disulfid
bond
residu
block
access
epitop
rule
possibl
next
use
detect
prp
treat
reduc
reagent
tributylphosphin
tbp
alkyl
reagent
mechlorethamin
mct
break
disulfid
bond
block
free
thiol
group
addit
antibodi
three
antibodi
use
control
direct
direct
antic
antibodi
detect
untreat
recombin
human
also
detect
prp
sampl
treat
tbp
mct
alon
fig
treatment
tbp
alon
decreas
intens
prp
probe
four
antibodi
howev
detect
prp
sampl
treat
tbp
mct
togeth
antic
antibodi
still
detect
prp
fig
result
similar
previou
observ
previous
use
peptid
membran
array
techniqu
often
use
map
antibodi
epitop
remap
epitop
antibodi
howev
unabl
find
convinc
epitop
antibodi
use
peptid
membran
array
cover
entir
human
prp
sequenc
residu
data
shown
result
consist
observ
report
moudjou
et
al
suggest
conform
epitop
even
though
abl
detect
denatur
prp
western
blot
treat
prpwt
endo
h
pngase
f
cleav
nlink
glycan
endo
h
treatment
significantli
chang
gel
profil
glycoform
ratio
prpwt
fig
contrast
significantli
reduc
intens
monoglycosyl
increas
intens
unglycosyl
form
fig
relev
chang
intens
diglycosyl
observ
two
monoglycosyl
speci
becam
undetect
treatment
endo
h
suggest
endo
h
remov
glycan
monoglycosyl
prp
two
site
hand
faint
band
migrat
kda
correspond
unglycosyl
deglycosyl
visibl
treat
sampl
probabl
deriv
monoglycosyl
prp
fig
treatment
pngase
f
three
differ
prp
speci
observ
band
migrat
kda
correspond
deglycosyl
unglycosyl
prp
fig
howev
prpwt
exhibit
band
migrat
kda
correspond
endogen
ntermin
truncat
fragment
confirm
endo
h
reduc
monoglycosyl
diglycosyl
prp
speci
proceed
examin
endo
h
pngase
f
treat
two
antibodi
includ
antic
antin
fig
reaffirm
evid
antibodi
antic
antin
antibodi
also
reveal
decreas
intens
diglycosyl
prp
dramat
decreas
intens
monoglycosyl
prp
speci
pngase
f
also
remov
glycan
use
two
antibodi
also
examin
prpsc
scjd
observ
chang
intens
di
monoglycosyl
prp
speci
treatment
endo
h
fig
pngase
f
remov
glycan
prpsc
well
sinc
two
mutat
significantli
increas
prp
aggreg
evidenc
protein
chemistri
studi
ask
whether
chang
organel
cellular
structur
induc
mutant
prp
readili
form
aggreg
cell
express
prpwt
examin
electron
microscopi
fig
although
organel
includ
mitochondria
nucleu
seem
ident
cell
lysosom
characterist
differ
cell
express
variou
prp
speci
compar
prpwt
cell
fig
cell
exhibit
enhanc
autophagi
fig
virtual
autophagi
observ
cell
fig
two
nlink
glycosyl
site
locat
residu
asnilethr
residu
residu
asnphethr
residu
believ
play
crucial
role
stabil
prion
protein
conform
natur
occur
mutat
residu
thr
ala
residu
phe
ser
fall
two
consensu
site
link
two
distinct
famili
prion
diseas
elimin
two
site
two
site
togeth
mutagenesi
hamster
prp
cell
induc
intracellular
accumul
mutant
protein
lehman
harri
observ
mous
prp
mutat
alon
cho
cell
fail
reach
cell
surfac
mutat
moreov
three
mutant
prp
acquir
prpsclike
physicochem
properti
reminisc
prpsc
limit
extent
prpwt
synthes
presenc
inhibitor
tunicamycin
use
cell
express
human
capellari
et
al
observ
reach
cell
surfac
even
though
mutat
elimin
glycosyl
first
site
indic
thr
ala
mutat
elimin
first
glycosyl
site
alter
physic
properti
mutant
protein
although
mutat
fall
within
second
glycosyl
site
asnphethr
residu
slightli
increas
effici
glycosyl
first
glycosyl
site
greatli
increas
effici
glycosyl
second
site
cultur
cell
current
studi
indic
two
mutant
prp
molecul
exhibit
increas
aggreg
although
small
amount
prpwt
aggreg
also
evid
absenc
tunicamycin
oligom
larg
aggreg
virtual
monomer
form
present
howev
monomer
speci
still
domin
despit
increas
amount
aggreg
sinc
major
recov
top
fraction
sucros
step
gradient
enhanc
tendenc
form
aggreg
may
result
intracellular
accumul
mutant
protein
mutat
chang
abil
reach
cell
surfac
although
mutat
may
significantli
chang
structur
around
epitop
previous
found
local
human
therefor
major
iprpc
associ
mutat
may
result
prp
intracellular
accumul
rais
possibl
iprpc
deriv
predominantli
intracellular
prp
speci
immunofluoresc
microscopi
tag
prp
also
indic
accumul
within
cell
wherea
distribut
insid
cell
cell
surfac
consist
previou
observ
addit
abnorm
protein
fold
two
mutat
also
significantli
alter
nlink
glycosyl
anticip
nlink
glycosyl
predict
algorithm
netnglyc
confirm
western
blot
analysi
complet
abolish
glycosyl
howev
also
exhibit
alter
glycosyl
blot
migrat
pkresist
faster
domin
monoglycosyl
prpsc
scjd
suggest
appar
molecular
weight
glycan
smaller
glycan
howev
use
two
monoclon
antibodi
demonstr
appar
molecular
weight
pkresist
prpsc
scjd
greater
prpsc
consist
previou
find
scrapi
prpsc
thu
combin
result
provid
evid
suggest
alter
composit
glycan
furthermor
analys
reveal
pi
pkresist
basic
pkresist
diglycosyl
acid
use
endo
h
confirm
larg
amount
glycan
immatur
origin
report
capellari
et
al
find
support
hypothesi
contain
modifi
glycan
endo
h
resist
molecul
fail
reach
cell
surfac
present
studi
demonstr
glycan
either
first
second
site
virtual
complet
digest
endo
h
monoglycosyl
interestingli
glycan
diglycosyl
significantli
digest
suggest
diglycosyl
matur
monoglycosyl
form
glycan
mous
hamster
brain
prpsc
character
mass
spectrometri
previou
report
glycosyl
two
nlink
consensu
site
mous
strain
directli
compar
mass
spectrometri
differ
nglycan
popul
two
site
observ
notabl
although
site
contain
major
neutral
compon
mani
minor
neutral
compon
observ
first
second
site
major
glycan
first
site
bi
triantennari
structur
mass
rang
approxim
kda
wherea
second
site
mainli
contain
tri
tetraantennari
structur
mass
rang
kda
therefor
molecular
mass
glycan
greater
second
site
first
site
differ
rang
kda
rang
oligosaccharid
prpc
pkresist
found
ident
rel
proport
glycan
differ
two
speci
compar
prpc
reduc
bisect
increas
tri
tetraantennari
glycan
nevertheless
date
mass
spectrometri
analysi
glycan
human
prpsc
pkresist
human
prp
report
glycan
two
monoglycosyl
speci
readili
differenti
western
blot
use
regular
antiprp
antibodi
wellcharacter
antibodi
gener
recombin
sheep
prp
immunogen
abl
discrimin
two
prp
speci
monoglycosyl
either
first
second
glycosyl
site
sheep
human
hamster
mous
addit
recogn
unglycosyl
prp
also
recogn
prp
speci
monoglycosyl
first
site
recogn
prp
speci
monoglycosyl
second
site
use
two
antibodi
confirm
molecular
mass
glycan
greater
second
first
site
although
also
detect
diglycosyl
sheep
prpc
detect
diglycosyl
sheep
prpsc
data
indic
molecular
mass
glycan
greater
second
first
site
human
pkresist
prpsc
scjd
similar
observ
scrapi
prpsc
howev
molecular
mass
glycan
second
site
seem
smaller
glycan
second
site
brain
prpsc
scjd
provid
evid
mutat
perturb
glycosyl
second
site
furthermor
present
studi
demonstr
speci
monoglycosyl
first
second
site
undetect
endo
h
treatment
therefor
mutat
similarli
alter
glycosyl
second
also
first
site
howev
glycan
diglycosyl
cleav
endo
h
indic
glycan
diglycosyl
prp
matur
although
epitop
local
sheep
correspond
human
local
sheep
correspond
human
map
studi
resolut
prpfab
crystal
complex
convent
peptid
scan
fail
local
prp
sequenc
result
epitop
believ
conformationdepend
agreement
result
report
demonstr
previous
reduct
alkyl
block
access
epitop
epitop
antic
break
disulfid
bond
prp
current
studi
data
reveal
reduct
prp
tbp
decreas
access
epitop
combin
reduct
alkyl
complet
block
access
provid
evid
access
epitop
depend
intact
disulfid
bond
ctermin
prp
epitop
block
mutat
well
suggest
mutat
may
also
ruptur
disulfid
bond
result
parallel
discoveri
conform
sensit
antiprp
antibodi
includ
also
report
lower
affin
prpwt
unexpectedli
detect
glycosyl
unglycosyl
prp
speci
three
type
cultur
cell
even
though
detect
brain
prpc
prpsc
epitop
becom
inaccess
wildtyp
mutant
prp
speci
remain
determin
sinc
amount
prpwt
use
seem
larg
indic
fig
unlik
inabl
detect
prp
cultur
cell
mainli
result
lower
affin
prp
autophagi
degrad
organel
unfold
protein
lysosom
pathway
consid
key
adapt
respons
prevent
death
stress
diseas
cell
natur
process
normal
occur
basal
level
cell
induc
varieti
condit
use
electron
microscopi
observ
autophagi
slightli
increas
cell
express
compar
cell
express
prpwt
surprisingli
autophagi
dramat
decreas
cell
express
human
highlight
possibl
paradox
relationship
autophagi
aggreg
sinc
largest
amount
prp
aggreg
also
observ
cell
express
mutant
worth
note
cytosol
prp
aggreg
recent
observ
activ
reticulon
inhibit
autophagi
imped
clearanc
cytosol
prp
aggreg
vitro
furthermor
reveal
activ
mediat
enhanc
interact
beclin
sinc
autophagi
believ
play
either
prosurviv
prodeath
role
determin
molecular
mechan
underli
differ
induct
autophagi
use
cell
model
would
present
import
avenu
develop
therapeut
strategi
protein
fold
disord
physiolog
pathophysiolog
iprpc
current
remain
unclear
propos
iprpc
involv
prion
alzheim
diseas
longterm
memori
storag
accord
recent
find
new
insight
mechan
underli
spontan
format
prp
aggreg
obtain
cell
model
would
signific
enhanc
understand
prion
diseas
also
diseas
involv
protein
misfold
phenylmethylsulfonyl
fluorid
pmsf
pk
n
ndiisopropylcarbodiimid
trifluoroacet
acid
piperidin
triisobutylsilan
dichloromethan
purchas
sigma
chemic
co
st
loui
mo
peptid
nglycosidas
f
pngase
f
purchas
new
england
biolab
beverli
use
accord
manufactur
protocol
reagent
includ
aminopeg
cellulos
membran
fmocamino
acid
obtain
intavi
san
marco
ca
purchas
anaspec
san
jose
ca
reagent
enhanc
chemiluminesc
ecl
plu
obtain
amersham
pharmacia
biotech
inc
piscataway
nj
magnet
bead
dynabead
tosylactiv
dynal
co
oslo
norway
recombin
human
kindli
provid
dr
witold
k
surewicz
depart
physiolog
biophys
case
western
reserv
univers
gene
protein
kindli
provid
dr
geoff
kneal
john
mcgeehan
biophys
laboratori
institut
biomed
biomolecular
scienc
univers
portsmouth
portsmouth
unit
kingdom
antiprp
antibodi
includ
mous
monoclon
antibodi
human
prp
residu
human
human
prp
cell
scienc
inc
canton
human
approxim
human
residu
antic
antin
also
use
human
neuroblastoma
cell
transfect
episom
vector
contain
prion
code
sequenc
use
cation
lipid
dotap
roch
appli
scienc
previous
describ
transfect
cell
grown
bulk
select
hygromycinresist
cultur
optimem
calf
serum
supplement
ironenrich
gibcobrl
hygromycin
b
calbiochem
la
jolla
ca
experi
cell
remov
flask
trypsin
count
number
cell
cell
cultur
seed
onto
petri
plate
incub
overnight
confluenc
complet
medium
supplement
serum
antibiot
consent
use
autopsi
materi
research
purpos
obtain
sampl
autopsi
perform
within
h
death
biopsi
brain
tissu
immedi
frozen
liquid
nitrogen
transfer
futur
use
wv
brain
homogen
prepar
volum
lysi
buffer
mm
tri
mm
nacl
nonidet
deoxychol
mm
edta
ph
requir
brain
homogen
centrifug
g
min
collect
supernat
pkdigest
sampl
incub
design
amount
pk
h
reaction
termin
addit
pmsf
final
concentr
mm
boil
sd
sampl
buffer
sd
mm
edta
glycerol
mm
tri
ph
minut
remov
media
cell
rins
three
time
pb
lyse
ml
lysi
buffer
ice
min
cell
lysat
centrifug
g
min
remov
nuclei
cellular
debri
supernat
incub
ml
prechil
methanol
h
centrifug
g
min
pellet
resuspend
lysi
buffer
gener
method
prepar
multipl
overlap
peptid
bound
cellulos
membran
describ
detail
block
skim
milk
tbst
h
prion
peptid
membran
probe
skim
milk
h
membran
wash
tbst
incub
hrpconjug
sheep
antimous
igg
h
final
wash
develop
ecl
western
blot
detect
reagent
amersham
pharmacia
membran
visual
use
biorad
fluoresc
imag
control
membran
probe
hrpconjug
sheep
antimous
igg
without
primari
antibodi
molecul
conjug
x
tosyl
activ
magnet
bead
ml
pb
h
bead
incub
bsa
pb
block
nonspecif
bind
prepar
bead
stabl
least
month
specif
captur
prpsc
perform
describ
incub
fraction
conjug
bead
x
bead
ml
bind
buffer
pb
ph
incub
constant
rotat
overnight
room
temperatur
prpcontain
bead
collect
extern
magnet
forc
unbound
molecul
solut
remov
follow
three
rins
wash
buffer
nonidet
pb
ph
bead
resuspend
sd
sampl
buffer
sd
mm
edta
glycerol
mm
tri
ph
heat
min
releas
bound
protein
recombin
prp
boil
equal
volum
x
sampl
buffer
sodium
dodecyl
sulfat
sd
mm
edta
glycerol
mm
trishcl
ph
describ
previous
sampl
incub
volum
prechil
methanol
h
follow
centrifug
g
min
pellet
resuspend
tbp
buffer
mm
tbp
urea
chap
mm
trishcl
ph
h
room
temperatur
incub
dark
alkyl
antitumor
drug
design
time
sampl
incub
prechil
methanol
centrifug
g
min
final
pellet
resuspend
sampl
buffer
subject
sdspage
immunoblot
variou
antiprp
antibodi
cell
lysat
incub
equal
volum
sarcosyl
min
ice
sampl
load
atop
step
sucros
gradient
centrifug
x
g
rotor
h
describ
minor
modif
centrifug
content
centrifug
tube
sequenti
remov
top
bottom
collect
fraction
aliquot
fraction
subject
immunoblot
analysi
describ
cell
cultur
embed
film
electron
microscopi
scienc
hatfield
pa
fix
glutaraldehyd
millonig
phosphat
buffer
ph
two
hour
room
temperatur
rins
phosphat
buffer
cell
postfix
ferrocyanidereduc
osmium
tetroxid
karnovski
two
hour
rins
distil
water
cell
soak
overnight
acidifi
uranyl
acet
anoth
rins
follow
dehydr
ascend
concentr
ethanol
passag
propylen
oxid
embed
polyb
polysci
warrington
pa
cell
film
crosssect
thin
section
stain
acidifi
methanol
uranyl
acet
follow
stain
sato
tripl
lead
stain
modifi
hanaichi
et
al
examin
jeol
electron
microscop
immunofluoresc
stain
prp
without
pk
comparison
transfect
cell
express
prpwt
grown
overnight
polydlysin
coat
coverslip
cell
fix
paraformaldehyd
minut
room
temperatur
block
perform
pbst
goat
serum
triton
hr
room
temperatur
rins
pb
cell
incub
room
temperatur
rins
pb
follow
fitcconjug
goat
antimous
igg
sigma
st
loui
mo
hour
room
temperatur
dark
wash
pb
coverslip
mount
slide
use
fluoresc
mount
medium
fluoromount
dapi
dako
carpenteria
ca
imunofluoresc
stain
pk
comparison
wild
type
cell
grown
ident
condit
describ
also
fix
paraformaldehyd
minut
room
temperatur
block
step
includ
pk
pk
posit
dish
along
pbst
later
condit
constant
except
sole
use
monoclon
antibodi
sampl
resolv
trishcl
criterion
precast
gel
biorad
sd
polyacrylamid
gel
electrophoresi
v
min
protein
gel
transfer
immobilonp
membran
pvdf
millipor
h
membran
incub
h
room
temperatur
either
antin
antic
primari
antibodi
probe
prp
molecul
follow
incub
hrpconjug
sheep
antimous
igg
monoclon
antibodi
donkeyanti
rabbit
igg
prp
band
spot
visual
kodak
film
ecl
plu
accord
manufactur
protocol
